Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CHMP Nod Little Consolation As Amgen's Imlygic Becomes Melanoma Also-Ran

This article was originally published in The Pink Sheet Daily

Executive Summary

Europe's top scientific panel gives positive review to product (also known as T-VEC) for advanced melanoma but the treatment landscape has been transformed by innovative competitors over the past few years.

You may also be interested in...



Amgen’s Imlygic Approval A Milestone For Oncolytic Cancer Vaccines

Company prices Imlygic (T-VEC) cancer vaccine at the average cost of $65,000, aims to launch within a week.

Merck Expands Keytruda Trial Collaboration With Amgen, Unveils Others

Merck’s sBLA for Keytruda in lung cancer has been accepted by FDA and granted an Oct. 2 action date, the firm announced. The company also revealed several new research collaborations to study Keytruda in more combination trials at ASCO.

Amgen’s T-VEC Gets FDA Panel Endorsement – But On Wrong Question?

Joint advisory committee votes 22-1 to approve T-VEC for metastatic melanoma but several members favor restricting use to patients in earlier stages of disease; FDA not asking the ‘right question’ for approval, NCI representative says.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS077914

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel